Health Counsel - House Energy and Commerce Committee (Rep. Frank Pallone); Counsel, Legislative Assistant - Rep. Kurt Schrader
Covered official positions, as disclosed on federal filings
The past 12 months
Clients
8
past 12 months
Filings
9
past 12 months
Agencies contacted
SENATEHOUSE OF REPRESENTATIVESCommerce, Dept of (DOC)Food & Drug Administration (FDA)Health & Human Services, Dept of (HHS)State, Dept of (DOS)U.S. Trade Representative (USTR)
Specific issues
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Health Issues · 2026 Q1
Outreach regarding cell therapies for autoimmune diseases.
Pharmacy · 2026 Q1
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Health Issues · 2026 Q1
Issues affecting healthcare manufacturing including supply chain, intellectual property, international trade, and tariffs.
Manufacturing · 2026 Q1
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. Pharmaceutical tariffs
Health Issues · 2026 Q1
NIH Federal grant issues FY27 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)